Pembrolizumab biosimilar (Shanghai Henlius Biotech Inc)

帕博利珠单抗生物类似药 (上海复宏汉霖生物技术股份有限公司)

Report date: 2026/04/08 15:42:06

Base Information

Drug NamePembrolizumab biosimilar (Shanghai Henlius Biotech Inc)
Drug Alias NameHLX-17
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGeorgiaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesAl Tiryaq Al-Khalawi Medical CompanyFosun Hanlin (Shenzhen) Biotechnology Co LtdShanghai Henlius Biotech Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungCarcinoma, Renal Cell +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A